Testosterone therapy for ED: when the questions are different

Testosterone therapy is not a default treatment for erectile dysfunction. ED is a clinical problem with multiple possible contributors; testosterone deficiency is a separate diagnosis that requires symptoms or signs plus consistently low measured levels under an appropriate evaluation. The AUA recommends assessing testosterone in men presenting with ED, while the Endocrine Society limits testosterone treatment to appropriately diagnosed hypogonadism. A single “low T” advertisement cannot settle either question.¹²

The distinction matters because two people may use the same phrase—“my testosterone is low”—for different problems. One may have an erection concern with a normal hormone evaluation. Another may have documented testosterone deficiency and symptoms, with ED among several concerns. A consultation should record both findings without assuming one caused the other.

Keep the ED and testosterone records side by side

The AUA ED guideline frames an erection problem as a reason for a broader medical, sexual and psychosocial history, with a focused examination and indicated testing. It recommends measuring morning serum total testosterone as part of evaluation. That test is an assessment step, not a conclusion that every person with ED needs TRT.¹

ED can be connected with vascular health, diabetes, medicines, psychological factors, relationship circumstances or other health conditions. It can also coexist with low testosterone without being wholly explained by it. A credible clinic needs a way to assess or refer for those other contributors rather than using one hormone result as a universal explanation.

What the hypogonadism guideline actually requires

The Endocrine Society recommends diagnosing hypogonadism only in men with compatible symptoms and signs and unequivocally and consistently low testosterone concentrations, measured appropriately and confirmed. It also lists circumstances in which testosterone treatment should not be started and calls for ongoing evaluation of benefits and adverse effects when used.²

This is more rigorous than a result in the low end of a lab’s reference range. The number depends on assay, timing, health state and interpretation. A clinic that offers testosterone after one isolated test without explaining why it fits the person’s symptoms is skipping the key diagnostic distinction.

The guideline does not make ED a single-item test for hypogonadism. Low libido, fewer morning erections or other symptoms may add context, but each is nonspecific. The clinician should be able to explain what diagnosis they are treating and why the proposed product is indicated for that diagnosis.

The TRT clinic question guide covers broad intake, monitoring and product selection. Here the specific challenge is whether an ED complaint is being converted into a testosterone sale without a complete ED and hormone assessment.

Read the treatment claim as a conditional statement

A practice might say, “TRT can help ED when low testosterone is the cause.” Even that statement needs nuance: group evidence and an individual diagnosis are not the same, and ED may persist because more than one factor is present. “TRT cures ED” drops the condition and implies a guaranteed outcome the guidance does not support.¹²

Ask what improvement the clinician expects to evaluate. Is the stated endpoint hormone-deficiency symptoms, erectile function, libido, energy, or a combination? Each endpoint needs a different way to check whether the plan is meeting its purpose. A lab value improving is not by itself proof that an erection problem has been resolved.

The clinician should also explain what happens if the original ED concern remains despite any change in testosterone. A plan with no route to further evaluation or referral is incomplete. Conversely, the existence of other ED care options does not make hormone assessment irrelevant when a person’s history genuinely suggests deficiency.

Five questions for the consultation

1. What findings support an ED assessment, and which possible contributors have been considered?
2. What exactly supports a testosterone-deficiency diagnosis, including repeat measurement and symptoms?
3. If TRT is proposed, which finished product and labeled indication match the diagnosis?
4. Which outcome will be followed separately for hormone symptoms and erectile function?
5. Who handles further ED assessment if the hormone plan does not address the original concern?

These are questions to bring to a clinician, not a home test or dosing protocol. A hormone-therapy practice should be able to explain its part of the decision and its referral path. The reader’s aim is a clear diagnosis and a responsible plan, rather than a prescription tied to a single symptom or number.